{
    "medicine_id": "27f0eaca61b03b23595c38fba3b23205015c3b70",
    "platform_id": "DB14730",
    "metadata": {
        "name": "Asparlas 750 U 1mL Injection solution",
        "composition": "750 U 1mL Calaspargase pegol",
        "clinical_particulars": {
            "therapeutic_indications": "This drug is is an asparagine specific enzyme indicated as a component of a multi agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years FDA label The pharmacokinetics of calaspargase pegol were examined when given in combination with multiagent chemotherapy in 124 patients with B cell lineage ALL L4890 The FDA approval of this drug was based on the achievement and maintenance of nadir serum asparaginase activity above the level of 0 1 U mL when administering calaspargase 2500 U m2 intravenously at 3 week intervals",
            "contraindications": {
                "disease": "Pancreatitis hepatotoxicity hemorrhage and thrombosis have been observed with calaspargase pegol use FDA label Pancreatitis Discontinue this drug in patients with pancreatitis and monitor blood glucose Hepatotoxicity Hepatic function should be tested regularly and trough levels of this drug should be measured during the recovery phase of the drug cycle FDA label Hemorrhage or Thrombosis Discontinue this drug in serious or life threatening hemorrhage or thrombosis In cases of hemorrhage identify the cause of hemorrhage and treat appropriately Administer anticoagulant therapy as indicated in thrombotic events FDA label A note on hypersensitivity Observe the patient for 1 hour after administration of calaspargase pegol for possible hypersensitivity FDA label In cases of previous hypersensitivity to this drug discontinue this drug immediately Lactation Advise women not to breastfeed while taking this drug FDA label Pregnancy There are no available data on the use of calaspargase pegol in pregnant women to confirm a risk of drug associated major birth defects and miscarriage Published literature studies in pregnant animals suggest asparagine depletion can cause harm to the animal offspring It is therefore advisable to inform women of childbearing age of this risk The background risk of major birth defects and miscarriage for humans is unknown at this time FDA label Pregnancy testing should occur before initiating treatment Advise females of reproductive potential to avoid becoming pregnant while taking this drug Females should use effective contraceptive methods including a barrier methods during treatment and for at least 3 months after the last dose There is a risk for an interaction between calaspargase pegol and oral contraceptives The concurrent use of this drug with oral contraceptives should be avoided Other non oral contraceptive methods should be used in women of childbearing potential FDA label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "The effect of this drug is believed to occur by selective killing of leukemic cells due to depletion of plasma L asparagine Leukemic cells with low expression of asparagine synthetase are less capable of producing L asparagine and therefore rely on exogenous L asparagine for survival FDA label When asparagine is depleted tumor cells cannot proliferate F2432 During remission induction one dose of SC PEG 2500 IU m2 results in a sustained therapeutic serum asparaginase activity SAA without excessive toxicity or marked differences in the proportion of patients with low end induction minimum residual disease MRD L4892 Pharmacodynamic PD response was studied through measurement of plasma and cerebrospinal fluid CSF asparagine concentrations with an LC MS MS assay liquid chromatography mass spectrometry Asparagine concentration in plasma was sustained below the assay limit of quantification for more than 18 days after one dose of calaspargase pegol 2 500 U m2 during the induction phase of treatment Average cerebrospinal asparagine concentrations decreased from a pretreatment concentration of 0 8 \u03bcg mL N 10 to 0 2 \u03bcg mL on Day 4 N 37 and stayed decreased at 0 2 \u03bcg mL N 35 25 days after the administration of one of 2 500 U m2 in the induction phase FDA label",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00304",
                        "description": "The therapeutic efficacy of Desogestrel can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00351",
                        "description": "The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00367",
                        "description": "The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00603",
                        "description": "The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00717",
                        "description": "The therapeutic efficacy of Norethisterone can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00783",
                        "description": "The therapeutic efficacy of Estradiol can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00823",
                        "description": "The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00834",
                        "description": "The therapeutic efficacy of Mifepristone can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00957",
                        "description": "The therapeutic efficacy of Norgestimate can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB00977",
                        "description": "The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB01395",
                        "description": "The therapeutic efficacy of Drospirenone can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB04839",
                        "description": "The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB06730",
                        "description": "The therapeutic efficacy of Gestodene can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB09123",
                        "description": "The therapeutic efficacy of Dienogest can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB09371",
                        "description": "The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB09389",
                        "description": "The therapeutic efficacy of Norgestrel can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB11619",
                        "description": "The therapeutic efficacy of Gestrinone can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB12474",
                        "description": "The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB13310",
                        "description": "The therapeutic efficacy of Ormeloxifene can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB13528",
                        "description": "The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB13563",
                        "description": "The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB13685",
                        "description": "The therapeutic efficacy of Quingestanol can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB13857",
                        "description": "The therapeutic efficacy of Demegestone can be decreased when used in combination with Calaspargase pegol"
                    },
                    {
                        "drugbank-id": "DB13981",
                        "description": "The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Calaspargase pegol"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}